These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23851167)

  • 1. Re: effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer.
    Traish AM; Morgentaler A
    J Steroid Biochem Mol Biol; 2013 Nov; 138():462. PubMed ID: 23851167
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer.
    Stanczyk FZ; Azen CG; Pike MC
    J Steroid Biochem Mol Biol; 2013 Nov; 138():10-6. PubMed ID: 23474436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to commentary.
    Stanczyk FZ
    J Steroid Biochem Mol Biol; 2013 Nov; 138():463. PubMed ID: 23851168
    [No Abstract]   [Full Text] [Related]  

  • 4. Simultaneous pharmacokinetic and pharmacodynamic analysis of 5α-reductase inhibitors and androgens by liquid chromatography tandem mass spectrometry.
    Upreti R; Naredo G; Faqehi AM; Hughes KA; Stewart LH; Walker BR; Homer NZ; Andrew R
    Talanta; 2015 Jan; 131():728-35. PubMed ID: 25281165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease.
    Hoque A; Yao S; Till C; Kristal AR; Goodman PJ; Hsing AW; Tangen CM; Platz EA; Stanczyk FZ; Reichardt JK; vanBokhoven A; Neuhouser ML; Santella RM; Figg WD; Price DK; Parnes HL; Lippman SM; Ambrosone CB; Thompson IM
    Urology; 2015 Mar; 85(3):616-20. PubMed ID: 25733274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of serum sex steroid hormone and 5α-androstane-3α,17β-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride.
    Kristal AR; Till C; Tangen CM; Goodman PJ; Neuhouser ML; Stanczyk FZ; Chu LW; Patel SK; Thompson IM; Reichardt JK; Hoque A; Platz EA; Figg WD; Van Bokhoven A; Lippman SM; Hsing AW
    Cancer Epidemiol Biomarkers Prev; 2012 Oct; 21(10):1823-32. PubMed ID: 22879203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of 5α-reductase inhibitors in prostate cancer prevention and treatment.
    Azzouni F; Mohler J
    Urology; 2012 Jun; 79(6):1197-205. PubMed ID: 22446342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of competitive and noncompetitive 5α-reductase inhibitors on serum and intra-prostatic androgens in beagle dogs.
    Zhao XF; Yang Y; Wang W; Qiu Z; Zhang P; Wang B
    Chin Med J (Engl); 2013 Feb; 126(4):711-5. PubMed ID: 23422194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potency of a novel saw palmetto ethanol extract, SPET-085, for inhibition of 5alpha-reductase II.
    Pais P
    Adv Ther; 2010 Aug; 27(8):555-63. PubMed ID: 20623347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5α-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models.
    Masoodi KZ; Ramos Garcia R; Pascal LE; Wang Y; Ma HM; O'Malley K; Eisermann K; Shevrin DH; Nguyen HM; Vessella RL; Nelson JB; Parikh RA; Wang Z
    Endocrinology; 2013 Jul; 154(7):2296-307. PubMed ID: 23671262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.
    Dutta A; Panja S; Virk RK; Kim JY; Zott R; Cremers S; Golombos DM; Liu D; Mosquera JM; Mostaghel EA; Barbieri CE; Mitrofanova A; Abate-Shen C
    Eur Urol; 2017 Oct; 72(4):499-506. PubMed ID: 28385453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Finasteride does not prevent bladder cancer: A secondary analysis of the Medical Therapy for Prostatic Symptoms Study.
    Sathianathen NJ; Fan Y; Jarosek SL; Lawrentschuk NL; Konety BR
    Urol Oncol; 2018 Jul; 36(7):338.e13-338.e17. PubMed ID: 29731413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.
    Festuccia C; Gravina GL; Muzi P; Pomante R; Angelucci A; Vicentini C; Bologna M
    J Urol; 2008 Jul; 180(1):367-72. PubMed ID: 18499161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer chemoprevention with 5α-reductase inhibitors.
    Nepple KG; Andriole GL
    Urol Oncol; 2012 Sep; 30(5):553-4. PubMed ID: 23193568
    [No Abstract]   [Full Text] [Related]  

  • 16. Androgen metabolism in the prostate of the finasteride-treated, adult rat: a possible explanation for the differential action of testosterone and 5 alpha-dihydrotestosterone during development of the male urogenital tract.
    George FW
    Endocrinology; 1997 Mar; 138(3):871-7. PubMed ID: 9048585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Finasteride.
    Chaudhary UB; Turner JS
    Expert Opin Drug Metab Toxicol; 2010 Jul; 6(7):873-81. PubMed ID: 20536414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do 5α-Reductase Inhibitors Raise Circulating Serum Testosterone Levels? A Comprehensive Review and Meta-Analysis to Explaining Paradoxical Results.
    Traish AM; Krakowsky Y; Doros G; Morgentaler A
    Sex Med Rev; 2019 Jan; 7(1):95-114. PubMed ID: 30098986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line.
    Amaral C; Varela C; Correia-da-Silva G; Tavares da Silva E; Carvalho RA; Costa SC; Cunha SC; Fernandes JO; Teixeira N; Roleira FM
    Biochimie; 2013 Nov; 95(11):2097-106. PubMed ID: 23933094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progesterone-induced stimulation of mammary tumorigenesis is due to the progesterone metabolite, 5α-dihydroprogesterone (5αP) and can be suppressed by the 5α-reductase inhibitor, finasteride.
    Wiebe JP; Rivas MA; Mercogliano MF; Elizalde PV; Schillaci R
    J Steroid Biochem Mol Biol; 2015 May; 149():27-34. PubMed ID: 25595041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.